News

Source — Source: PIB ///Category — GS Paper 2 ///Published — 2026-01-30 ///Exam — Both Prelims and Mains ///Tags — Rapid Fire CA, Quick Facts For Prelims, GS Paper - 2 ///Source — Source: PIB ///Category — GS Paper 2 ///Published — 2026-01-30 ///Exam — Both Prelims and Mains ///Tags — Rapid Fire CA, Quick Facts For Prelims, GS Paper - 2 ///

Source: PIB · GS Paper 2

Amendments to New Drugs and Clinical Trials Rules, 2019

The Union Ministry of Health and Family Welfare has introduced amendments to the NDCT Rules, 2019 to streamline drug research approvals, cutting down timelines by up to 90 days. These reforms, aligned with the Jan Vishwas principle, aim to position India as a global hub for pharmaceutical R&D and are crucial for UPSC aspirants studying health governance and regulatory reforms.

2026-01-30

Published

Source: PIB

Source

Quiz Questions

Article

Key Facts and Data Points

Waiver of Test Licence: Non‑commercial manufacture of small‑quantity drugs for research no longer needs a CDSCO test licence; a simple prior‑intimation suffices.
Exclusions: High‑risk categories – cytotoxic, narcotic, and psychotropic drugs – still require a licence.
Timeline Reduction:
Overall drug development cycle saved: 90 days.
For licence‑required categories, processing time cut from 90 to 45 days.
Clinical Studies: Prior permission for low‑risk Bioavailability/Bioequivalence (BA/BE) studies removed; online intimation now sufficient.
Digital Integration: New modules on National Single Window System (NSWS) and SUGAM portal for paperless submissions.
Policy Rationale: Aligns with Jan Vishwas (trust‑based) reforms to boost ease of doing business in pharma.

Background and Context

The New Drugs and Clinical Trials (NDCT) Rules, 2019 were framed to regulate drug approvals and clinical trials in India.
Earlier, researchers faced lengthy licence procedures, hampering timely R&D and discouraging foreign investment.
The amendments are part of the broader Ease of Doing Business agenda and aim to make India a preferred destination for pharmaceutical R&D.

Significance for India / Governance / Policy

Accelerates Innovation: Faster approvals reduce time‑to‑market for new drugs, enhancing public health outcomes.
Economic Impact: Encourages domestic and foreign pharma companies to set up R&D centres, generating employment and export earnings.
Regulatory Efficiency: Optimises CDSCO manpower and promotes a trust‑based, less‑bureaucratic approach.
Global Competitiveness: Positions India alongside countries like the USA, EU, and Singapore in clinical research infrastructure.

Related Constitutional / Legal Provisions

Article 21 (Right to Health) – faster drug approvals can improve health services.
Section 3 of the Drugs and Cosmetics Act, 1940 – empowers the central government to frame rules for drug regulation, under which NDCT Rules are issued.
Ease of Doing Business initiatives under the National Trade Policy – these amendments reflect the policy’s intent.

References

Drugs and Clinical Trials Rules, 2019